🔗 Share this article

While America undertakes sweeping revisions to its vaccination guidelines, a particular individual has surfaced somewhat surprisingly: Tracy Beth Høeg, a US-based sports physician and epidemiologist who initially gained attention by questioning Covid shots during the global health crisis and has focused upon potential deaths after Covid immunization in her short time at the FDA.

Scheduled Shifts to Childhood Vaccine Schedule

Health officials planned to unveil major changes to the childhood immunization program recently, bringing the US with Denmark’s national calendar, sources say – a substantial departure that would place the US at odds with much of the world with insufficient data for improved outcomes. The planned update has been postponed until the next year.

Instead of the top vaccines chief, Dr. Høeg is set to speak at the event. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the division this calendar year.

A New Direction at the Agency

This interim role could signify a tighter collaboration between the pharmaceutical and vaccine divisions as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it points to a greater focus upon rolling back already-approved vaccines at the FDA.

The new acting director has frequently advocated for ending some childhood vaccine recommendations in the US so as to align more in line with Denmark, a nation with universal health coverage and a number of inhabitants roughly the size of Wisconsin’s.

So far statements, she has continued to focus on vaccines – traditionally the domain of Prasad, director of the FDA’s CBER – as opposed to medication approval.

Doubts Over Expertise

The appointee has no apparent experience in drug development, approval processes or management, which has been customary for former heads of the biologics center. She has served at the FDA as a key advisor to the agency head and the vaccine center since spring.

“She appears not to have the requisite experience” for leading the CDER, remarked a neurologist and psychiatrist. “She’s never run a scientific study. She has no expertise in managing a major agency. She is not an expert in industry regulation.”

Former directors of CBER would “be deeply familiar with laws and regulations and the science of pharmaceutical innovation”, noted Janet Woodcock. “Frankly, she doesn’t have the sort of resume that prior appointees who led the center have had.”

The drug center has an vast range of responsibilities at the FDA, Woodcock pointed out.

“Everybody just pays attention on the innovative therapies, but the generic drug division authorizes numerous off-brand pharmaceuticals. There is also a biosimilars program, OTC medication office and more, and every single one need to be supervised,” she noted. “The area you overlook, that is the part that I always told people is going to cause problems.”

There is also, a significant leadership aspect to the position, which manages more than 5,000 personnel. “It is a massive management job, if you execute it properly,” the former official said.

Response and Disputed Initiatives

In response to inquiries about Dr. Høeg's qualifications and whether this selection indicates increased cooperation among agency officials on vaccines, a press secretary stated that the “questions rely on flawed presumptions”.

“Her resume is consistent with the functions of her position,” the spokesperson stated, citing the period Høeg spent counseling the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

As acting director, Høeg takes over the commissioner’s new expedited review system, a controversial rapid therapy clearance system that allegedly troubled her former heads. “By what process are these drugs being chosen for this voucher program? Who makes the choices?” Dr. Howard asked. “There’s a lot of lack of transparency occurring at the regulatory body right now.”

Broadly speaking, he said, “the Food and Drug Administration seems to be moving towards more relaxed rules of pharmaceuticals, except for immunizations.”

Established History on Immunizations

With immunizations, Dr. Høeg has a clearer, if problematic, history, Howard said. She released a study using non-validated volunteer-provided data to assess the incidence of heart inflammation after COVID-19 immunization. She counseled the state of Florida top health official Dr. Joseph Ladapo, who was said to have modified findings to suggest Covid vaccines are more dangerous than they are.

Included in her “desired changes” for the incoming federal leadership encompassed changing regulations for recently developed shots and discontinuing “optional” immunizations, she stated after the election on a audio program. At the agency, Dr. Høeg has reportedly floated the idea of preventing teenage boys from obtaining Covid vaccines.

“She’s an thorough dogmatist who starts off with her preconceived notions and works backwards to accommodate the science in a very misleading, dishonest way,” Dr. Howard stated.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg joined other contrarians, {like|